Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model

Journal of Immunology

Volumn 190, Issue 5, 2013, Pages 2464-2471

  Sevko, Alexandra ^a   Michels, Tillmann ^a   Vrohlings, Melissa ^a   Umansky, Ludmila ^b   Beckhove, Philipp ^b   Kato, Masashi ^c   Shurin, Galina V ^d   Shurin, Michael R ^d   Umansky, Viktor ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c CHUBU UNIVERSITY   (Japan)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN B; MITOGEN ACTIVATED PROTEIN KINASE P38; PACLITAXEL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CHRONIC INFLAMMATION; CONTROLLED STUDY; DRUG MECHANISM; IN VIVO STUDY; LYMPHOCYTE FUNCTION; MELANOMA SKIN CANCER; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPPRESSOR CELL; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CALGRANULIN B; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; IMMUNOSUPPRESSION; INFLAMMATION; MELANOMA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASES; MYELOID CELLS; PACLITAXEL; PRIMARY CELL CULTURE; SKIN NEOPLASMS; SPLEEN; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84874232680     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202781     Document Type: Article

References (39)

1. Shurin, M. R., H. Naiditch, D. W. Gutkin, V. Umansky, and G. V. Shurin. 2012. ChemoImmunoModulation: immune regulation by the antineoplastic chemotherapeutic agents. Curr. Med. Chem. 19: 1792-1803.
2. Shurin, G. V., I. L. Tourkova, and M. R. Shurin. 2008. Low-dose chemotherapeutic agents regulate small Rho GTPase activity in dendritic cells. J. Immunother. 31: 491-499.
3. Kaneno, R., G. V. Shurin, I. L. Tourkova, and M. R. Shurin. 2009. Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J. Transl. Med. 7: 58.
4. Shurin, G. V., I. L. Tourkova, R. Kaneno, and M. R. Shurin. 2009. Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J. Immunol. 183: 137-144.
5. Zhong, H., B. Han, I. L. Tourkova, A. Lokshin, A. Rosenbloom, M. R. Shurin, and G. V. Shurin. 2007. Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin. Cancer Res. 13: 5455-5462.
6. Ma, Y., G. V. Shurin, D. W. Gutkin, and M. R. Shurin. 2012. Tumor associated regulatory dendritic cells. Semin. Cancer Biol. 22: 298-306.
7. Wu, L., C. Yan, M. Czader, O. Foreman, J. S. Blum, R. Kapur, and H. Du. 2012. Inhibition of PPARg in myeloid-lineage cells induces systemic inflammation, immunosuppression, and tumorigenesis. Blood 119: 115-126.
8. Gabrilovich, D. I., S. Ostrand-Rosenberg, and V. Bronte. 2012. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12: 253-268.
9. Marigo, I., L. Dolcetti, P. Serafini, P. Zanovello, and V. Bronte. 2008. Tumorinduced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 222: 162-179.
10. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.
11. Filipazzi, P., V. Huber, and L. Rivoltini. 2012. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol. Immunother. 61: 255-263.
12. Montero, A. J., C. M. Diaz-Montero, C. E. Kyriakopoulos, V. Bronte, and S. Mandruzzato. 2012. Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J. Immunother. 35: 107-115.
13. Meyer, C., A. Sevko, M. Ramacher, A. V. Bazhin, C. S. Falk, W. Osen, I. Borrello, M. Kato, D. Schadendorf, M. Baniyash, and V. Umansky. 2011. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc. Natl. Acad. Sci. USA 108: 17111-17116.
14. Lesokhin, A. M., T. M. Hohl, S. Kitano, C. Cortez, D. Hirschhorn-Cymerman, F. Avogadri, G. A. Rizzuto, J. J. Lazarus, E. G. Pamer, A. N. Houghton, et al. 2012. Monocytic CCR2+ myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res. 72: 876-886.
15. Poschke, I., Y. Mao, L. Adamson, F. Salazar-Onfray, G. Masucci, and R. Kiessling. 2012. Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines. Cancer Immunol. Immunother. 61: 827-838.
16. Toh, B., X. Wang, J. Keeble, W. J. Sim, K. Khoo, W. C. Wong, M. Kato, A. Prevost-Blondel, J. P. Thiery, and J. P. Abastado. 2011. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol. 9: e1001162.
17. Filipazzi, P., R. Valenti, V. Huber, L. Pilla, P. Canese, M. Iero, C. Castelli, L. Mariani, G. Parmiani, and L. Rivoltini. 2007. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 25: 2546-2553.
18. Kato, M., M. Takahashi, A. A. Akhand, W. Liu, Y. Dai, S. Shimizu, T. Iwamoto, H. Suzuki, and I. Nakashima. 1998. Transgenic mouse model for skin malignant melanoma. Oncogene 17: 1885-1888.
19. Umansky, V., O. Abschuetz, W. Osen, M. Ramacher, F. Zhao, M. Kato, and D. Schadendorf. 2008. Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors. Cancer Res. 68: 9451-9458.
20. Campbell, J., C. J. Ciesielski, A. E. Hunt, N. J. Horwood, J. T. Beech, L. A. Hayes, A. Denys, M. Feldmann, F. M. Brennan, and B. M. Foxwell. 2004. A novel mechanism for TNF-α regulation by p38 MAPK: involvement of NF-kB with implications for therapy in rheumatoid arthritis. J. Immunol. 173: 6928-6937.
21. Sunahori, K., M. Yamamura, J. Yamana, K. Takasugi, M. Kawashima, H. Yamamoto, W. J. Chazin, Y. Nakatani, S. Yui, and H. Makino. 2006. The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kB and p38 mitogen-activated protein kinase in rheumatoid arthritis. Arthritis Res. Ther. 8: R69.
22. Hermani, A., B. De Servi, S. Medunjanin, P. A. Tessier, and D. Mayer. 2006. S100A8 and S100A9 activate MAP kinase and NF-kB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp. Cell Res. 312: 184-197.
23. Baniyash, M. 2006. Chronic inflammation, immunosuppression and cancer: new insights and outlook. Semin. Cancer Biol. 16: 80-88.
24. Perdiguero, E., P. Sousa-Victor, V. Ruiz-Bonilla, M. Jardí, C. Caelles, A. L. Serrano, and P. Muñoz-Cánoves. 2011. p38/MKP-1-regulated AKT coordinates macrophage transitions and resolution of inflammation during tissue repair. J. Cell Biol. 195: 307-322.
25. Kim, C., Y. Sano, K. Todorova, B. A. Carlson, L. Arpa, A. Celada, T. Lawrence, K. Otsu, J. L. Brissette, J. S. Arthur, and J. M. Park. 2008. The kinase p38a serves cell type-specific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression. Nat. Immunol. 9: 1019-1027.
26. Ho, F. M., C. C. Lai, L. J. Huang, T. C. Kuo, C. M. Chao, and W. W. Lin. 2004. The anti-inflammatory carbazole, LCY-2-CHO, inhibits lipopolysaccharideinduced inflammatory mediator expression through inhibition of the p38 mitogen-activated protein kinase signaling pathway in macrophages. Br. J. Pharmacol. 141: 1037-1047.
27. Gajewski, T. F. 2007. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin. Cancer Res. 13: 5256-5261.
28. Sevko, A., V. Kremer, C. Falk, L. Umansky, M. R. Shurin, G. V. Shurin, and V. Umansky. 2012. Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice. J. Immunotoxicol. 9: 275-281.
29. Zhao, F., C. Falk, W. Osen, M. Kato, D. Schadendorf, and V. Umansky. 2009. Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. Clin. Cancer Res. 15: 4382-4390.
30. Baldassare, J. J., Y. Bi, and C. J. Bellone. 1999. The role of p38 mitogenactivated protein kinase in IL-1b transcription. J. Immunol. 162: 5367-5373.
31. Ajibade, A. A., Q. Wang, J. Cui, J. Zou, X. Xia, M. Wang, Y. Tong, W. Hui, D. Liu, B. Su, et al. 2012. TAK1 negatively regulates NF-kB and p38 MAP kinase activation in Gr-1+CD11b+ neutrophils. Immunity 36: 43-54.
32. Zhou, F. H., B. K. Foster, X. F. Zhou, A. J. Cowin, and C. J. Xian. 2006. TNF-α mediates p38 MAP kinase activation and negatively regulates bone formation at the injured growth plate in rats. J. Bone Miner. Res. 21: 1075-1088.
33. Gao, D., and C. Bing. 2011. Macrophage-induced expression and release of matrix metalloproteinase 1 and 3 by human preadipocytes is mediated by IL-1b via activation of MAPK signaling. J. Cell. Physiol. 226: 2869-2880.
34. Chae, H. J., S. C. Kim, S. W. Chae, N. H. An, H. H. Kim, Z. H. Lee, and H. R. Kim. 2001. Blockade of the p38 mitogen-activated protein kinase pathway inhibits inducible nitric oxide synthase and interleukin-6 expression in MC3T3E-1 osteoblasts. Pharmacol. Res. 43: 275-283.
35. Chen, C., Y. H. Chen, and W. W. Lin. 1999. Involvement of p38 mitogenactivated protein kinase in lipopolysaccharide-induced iNOS and COX-2 expression in J774 macrophages. Immunology 97: 124-129.
36. Lokuta, M. A., and A. Huttenlocher. 2005. TNF-α promotes a stop signal that inhibits neutrophil polarization and migration via a p38 MAPK pathway. J. Leukoc. Biol. 78: 210-219.
37. Michels, T., G. V. Shurin, H. Naiditch, A. Sevko, V. Umansky, and M. R. Shurin. 2012. Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner. J. Immunotoxicol. 9: 292-300.
38. Gebhardt, C., J. Németh, P. Angel, and J. Hess. 2006. S100A8 and S100A9 in inflammation and cancer. Biochem. Pharmacol. 72: 1622-1631.
39. Apetoh, L., F. Végran, S. Ladoire, and F. Ghiringhelli. 2011. Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies. Curr. Mol. Med. 11: 365-372.